Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 11.94B +442.9% |
| Revenue (ttm) | 622.01M +14.1% |
| Net Income | -300.91M |
| EPS | -2.17 |
| Shares Out | 140.86M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,377,492 |
| Open | 86.93 |
| Previous Close | 87.32 |
| Day's Range | 84.53 - 87.10 |
| 52-Week Range | 15.01 - 95.49 |
| Beta | 1.27 |
| Analysts | Strong Buy |
| Price Target | 106.09 (+25.2%) |
| Earnings Date | Aug 4, 2026 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2025, Arrowhead Pharmaceuticals's revenue was $829.45 million, an increase of 23258.15% compared to the previous year's $3.55 million. Losses were -$1.63 million, -99.73% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $106.09, which is an increase of 25.20% from the latest price.
News
Arrowhead price target raised to $123 from $101 at B. Riley
B. Riley raised the firm’s price target on Arrowhead (ARWR) to $123 from $101 and keeps a Buy rating on the shares.
Arrowhead completes enrollment in Phase 3 YOSEMITE trial
Arrowhead (ARWR) Pharmaceuticals announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran, the company’s investigational RNA iHnterference, RNAi, therapeut...
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed enrollment in the global Phase 3 YOSEMITE clinical trial of zodasiran,...
Arrowhead price target raised to $115 from $100 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Arrowhead (ARWR) to $115 from $100 and keeps a Buy rating on the shares. The firm says the SHASTA Phase 3 data…
Arrowhead price target raised to $120 from $100 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Arrowhead (ARWR) to $120 from $100 and keeps an Overweight rating on the shares. The firm increased its view of the odds…
Arrowhead price target raised to $126 from $110 at Piper Sandler
Piper Sandler analyst Edward Tenthoff raised the firm’s price target on Arrowhead (ARWR) to $126 from $110 and keeps an Overweight rating on the shares. The Phase III SHASTA-3 and…
Arrowhead price target raised to $115 from $90 at Chardan
Chardan analyst Keay Nakae raised the firm’s price target on Arrowhead (ARWR) to $115 from $90 and keeps a Buy rating on the shares after the company reported that both…
Arrowhead Pharmaceuticals (ARWR) Stock Soars on Strong Phase 3 Trial Results
Arrowhead Pharmaceuticals stock saw major gains after the company announced new results from a Phase 3 trial.
Arrowhead announces Phase 3 SHASTA-3, SHASTA-4 met primary endpoint
Arrowhead (ARWR) Pharmaceuticals announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia, a condition that si...
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results for the global Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran ...
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discus...
Arrowhead price target raised to $95 from $88 at JPMorgan
JPMorgan raised the firm’s price target on Arrowhead (ARWR) to $95 from $88 and keeps an Overweight rating on the shares. The company’s SHASTA-3/4 readout in severe hypertriglyceridemia remains one…
Arrowhead initiated with a Buy at Stifel
Stifel analyst James Condulis initiated coverage of Arrowhead (ARWR) with a Buy rating and $98 price target. SASHTA-3/4 results should establish plozasiran as “a best-in-class drug,” argues the analys...
Arrowhead Pharmaceuticals Transcript: Investor update
The cardiometabolic pipeline leverages RNAi technology to address both rare and prevalent lipid disorders, with REDEMPLO already launched and multiple late-stage programs advancing. Key upcoming milestones include pivotal data for plozasiran and zodasiran, and first human data for the dual-targeting DIMER siRNA, all targeting significant unmet needs in hyperlipidemia and ASCVD.
Arrowhead Pharmaceuticals Slides: Investor update
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on June 29, 2026.
Arrowhead receives MAA in the EU for REDEMPLO
Arrowhead (ARWR) Pharmaceuticals announced that the European Commission has formally granted marketing authorization for REDEMPLO, a small interfering RNA medicine, as an adjunct to diet to reduce tri...
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the European Commission (EC) has formally granted marketing authorization for REDEMPLO®...
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host a 2026 Summer Series of R&D webinars that highlight multiple clinical stage...
Arrowhead Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted a strategic shift toward commercial execution, with a focus on cardiometabolic diseases and upcoming pivotal data for Redemplo. Early commercial results are promising, with expanded patient identification and positive payer feedback. The pipeline includes innovative obesity and liver disease programs.
Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a robust siRNA pipeline, with pivotal data for plozasiran in SHTG expected in Q3 and strong commercial uptake for REDEMPLO. Obesity and CNS programs are progressing, with key updates and new cohorts planned for the second half of the year.
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: 2026 Jefferies Global ...
Arrowhead presents interim results from Phase 1/2a trial of ARO-INHBE
Arrowhead (ARWR) Pharmaceuticals presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company’s investigational RNA interference therapeutic being developed as a potential trea...
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented interim results from a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational...